Clinical trials: Pediatric Tumor of Brain
Pediatric Brain Tumors, Genomics
GenoDrugP 2025: Study on Three-dimensional Models Derived From Brain Tumors in Pediatric Patients
Central nervous system tumours are the most common solid tumours and the leading cause of cancer mortality in children, with high biological and prognostic heterogeneity.
- Conditions
- Pediatric Brain Tumors, Genomics, Epigenetic
- Trial name
- NCT07417072
- Testing
- Genomic DNA analysis of biological samples
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Meyer Children's Hospital IRCCS
Headache, Urinary Incontinence
Pediatric Patient Experience on a Diagnostic Path
The trial will determine the impact of an information- and education-focused interventions on the anxiety levels, and patients' experiences as well as satisfaction of patients aged 10-14 and their caregivers during the MR…
- Conditions
- Headache, Urinary Incontinence, Growth Deficiency, Visual Impairment
- Trial name
- NCT05199363
- Testing
- Information leaflet, Educational movie, Demonstration
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Children's Memorial Health Institute, Poland
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma
Phase I Study of Marizomib + Panobinostat for Children With DIPG
This research study is evaluating the safety, tolerability and preliminary efficacy of the drugs marizomib and panobinostat in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
- Conditions
- Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer
- Trial name
- DIPG (NCT04341311)
- Testing
- Marizomib, Panobinostat
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Dana-Farber Cancer Institute
Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
This is a multi-site study with plerixafor in pediatric cancer patients. The study will be conducted in 2 stages: Stage 1 is a dose-escalation study.
- Conditions
- Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT01288573
- Testing
- plerixafor
- Where
- 27 sites in Belgium, Czechia and 10 more
- Volunteers
- 46 people
- Sponsor
- Genzyme, a Sanofi Company
Childhood Cancer
Inattention in Childhood Cancer Survivors
Specific Aim 1: To assess the feasibility and acceptability of a home-based, computerized cognitive training program with survivors of central nervous system-impacting pediatric cancer (e.g.
- Trial name
- TRICCS (NCT00636337)
- Testing
- Attention Training
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Cerebral Palsy, Pediatric ALL
Use of Integrated Pulmonary Index Monitorisation in Children Undergoing Botulinum Toxin Injection
This study aimed to detect hypoxia early with ıntegrated pulmonary index monitoring compared to saturation.
- Trial name
- NCT05724030
- Testing
- integrated pulmonary index, saturation
- Where
- Turkey (Türkiye)
- Volunteers
- 69 people
- Sponsor
- Kocaeli University
Glioma, Malignant, Ependymoma
In Vitro Models From Pediatric Brain Tumors
Tumors of the Central Nervous System (CNS) represent the leading cause of cancer-related deaths in children. Current treatment options are not curative for most malignant histologies, and intense preclinical and clinical research…
- Conditions
- Glioma, Malignant, Ependymoma, Medulloblastoma
- Trial name
- PBTS23 (NCT06499636)
- Testing
- other
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Brain Tumor, Pediatric, Medulloblastoma, Pediatric
Components of Social Functioning in Survivors of Pediatric Brain Tumors
Children with brain tumors are at risk for a number of psychological late effects, including neurocognitive and social deficits.
- Trial name
- NCT03361033
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- St. Jude Children's Research Hospital
Pediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine Glioma
Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children
Although DIPG is not curable, re-irradiation with a modest total dose and short treatment time provides good palliation of symptoms, improves quality of life, delays disease progression and has minimal and manageable toxicity.
- Trial name
- NCT01777633
- Testing
- Palliative re-irradiation for progressive DIPG in children
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Hadassah Medical Organization
Pediatric Brain Tumor
Survivors Journey+
The main goal of this pilot randomized controlled trial is to learn if an online program called "Survivors Journey" (SJ+) can help teens and young adults, ages 15-25, who are Pediatric Brain Tumor Survivors (PBTS), and their…
- Trial name
- SJ (NCT07321353)
- Testing
- Survivor's Journey+
- Where
- 2 sites in United States
- Volunteers
- 72 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood
COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors
Many pediatric brain and solid tumors have altered epigenetic landscapes, and altered DNA methylation. As such this study is a Phase I/Ib study of combined 5'Azacitidine with an escalating dose of carboplatin for all…
- Conditions
- Recurrent Childhood CNS Tumor, Ependymoma, Recurrent Childhood, Childhood Solid Tumor
- Trial name
- COZMOS (NCT03206021)
- Testing
- 5 Azacytidine
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- The Hospital for Sick Children
Cognitive Impairment, Cognitive Decline
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric…
- Conditions
- Cognitive Impairment, Cognitive Decline, Radiotherapy Side Effect, Radiotherapy; Complications
- Trial name
- LiBRA (NCT06051240)
- Testing
- Lithium
- Where
- 2 sites in Sweden
- Volunteers
- 84 people
- Sponsor
- Region Stockholm
Cancer
Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
This study aims to determine the efficacy of daily sirolimus and celecoxib, with low dose etoposide alternating with cyclophosphamide for pediatric participants with relapsed or refractory tumors.
- Trial name
- AflacST1502 (NCT02574728)
- Testing
- Sirolimus, Celecoxib, Etoposide
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating young patients with…
- Trial name
- NCT00572182
- Testing
- MK-0752
- Where
- 12 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pediatric Brain Tumor Consortium